New Hope for Dravet Syndrome as Experimental Drug Reduces Seizures by Up to 91%

Medical breakthrough brings new hope for children with Dravet syndrome, a severe genetic epilepsy that has long been difficult to treat. International clinical trial results show that the experimental drug zorevunersen can reduce seizure frequency by up to 91% and significantly improve patients’ quality of life.

The study, led by University College London (UCL) and Great Ormond Street Hospital (GOSH), was published in The New England Journal of Medicine. In addition to seizure relief, the therapy shows early evidence of the ability to improve cognitive and behavioural function in children.

Dravet syndrome is more than ordinary epilepsy. The rare condition is caused by a mutation in the SCN1A gene, which prevents nerve cells from communicating normally. Consequently, patients experience recurrent seizures, developmental delays, and a risk of premature death.

Zorevunersen works in a unique way by directly targeting the root cause. The drug encourages the healthy copy of the SCN1A gene to produce more of the protein that neurons need, thereby restoring stabilised brain cell function.

The trial involved 81 children aged 2 to 18 years in the United Kingdom and the United States. Before treatment, participants averaged 17 seizures per month.

The results were remarkable. In the group receiving a 70 mg dose, seizure frequency fell by between 59% and 91% during the first 20 months of follow-up. Most reported side effects were mild.

Professor Helen Cross, Director of the UCL Institute of Child Health, expressed her excitement about the development: ‘I often see patients with genetic epilepsy that is difficult to treat, where the impact goes beyond seizures, and it is deeply distressing when treatment options are limited. This new therapy could help children with Dravet syndrome lead healthier and happier lives.’

This medical breakthrough has been felt directly by families of patients, including Freddie, eight, from Huddersfield. Since taking part in the trial in 2021, his seizure pattern has shifted dramatically from dozens of episodes a night to as few as one or two brief seizures every few days.

‘This trial has completely transformed our lives. We now have a life we never imagined, and most importantly, a life Freddie can enjoy,’ said Lauren, Freddie’s mother.

Galia Wilson, Chair of Trustees of Dravet Syndrome UK, welcomed the results and hopes that the ongoing phase III trials will soon provide certainty for thousands of affected families. The collaboration between the research community and industry is expected to lay the foundations for a more responsive ecosystem of rare-disease therapies in the future. (Science Daily/Z-2)